Novartis Advances Cancer Treatment Manufacturing Strategy with New Radioligand Facility in Dallas Fort Worth Region

Novartis Advances Cancer Treatment Manufacturing Strategy with New Radioligand Facility in Dallas Fort Worth Region

(IN BRIEF) Novartis has announced plans to establish a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, with operations expected to begin in 2028. The new site will expand the company’s U.S. manufacturing network and support growing demand for targeted cancer treatments. The facility will be Novartis’ fifth radioligand therapy manufacturing site in the United States and part of a broader $23 billion investment program to expand U.S. operations. The Texas site will create jobs in bioengineering and advanced manufacturing while helping ensure timely delivery of customized radioligand therapy doses to patients. The expansion supports Novartis’ ongoing development of radioligand therapies for multiple cancer types and treatment stages.

(PRESS RELEASE) BASEL, 25-Feb-2026 — /EuropaWire/ — Novartis has announced plans to build a new radioligand therapy (RLT) manufacturing facility in Denton, Texas, expanding its U.S. production network for advanced cancer treatments. The purpose-built site will cover approximately 46,000 square feet and will become the company’s fifth RLT manufacturing facility in the United States and its first such site in Texas. The project forms part of Novartis’ broader $23 billion investment program aimed at strengthening its U.S. manufacturing and research capabilities.

Construction of the Denton facility is expected to begin during 2026, with operations scheduled to start in 2028. The site will support the production of customized radioligand therapy treatments and is expected to generate new employment opportunities in areas such as bioengineering, advanced manufacturing, quality assurance, and operational management, contributing to economic development in the Denton and Dallas–Fort Worth region.

Novartis CEO Vas Narasimhan highlighted the growing importance of radioligand therapy in cancer treatment and emphasized that expanding manufacturing capacity will help the company meet rising demand for these specialized therapies. The addition of the Texas facility will strengthen the company’s ability to deliver radioligand therapies efficiently, ensuring that patients receive treatment within the required timeframes.

Texas Governor Greg Abbott welcomed the investment, noting the state’s role as a major biotechnology center and emphasizing that the new facility will create skilled jobs while strengthening supply chains for advanced cancer treatments.

Once operational, the Denton site will become part of Novartis’ integrated radioligand therapy manufacturing network in the United States. Existing facilities are located in New Jersey, Indiana, and California, with another site recently announced in Florida. The network is designed to provide nationwide manufacturing coverage and has consistently enabled more than 99 percent of radioligand therapy doses to be delivered to patients on their scheduled treatment day. Because each dose is individually prepared and highly time-sensitive, locating production facilities close to treatment centers is essential for reliable delivery.

Radioligand therapy represents a targeted approach to cancer treatment in which radioactive molecules are directed specifically to tumor cells. By combining precision targeting with therapeutic radiation, these treatments aim to destroy cancer cells while limiting damage to surrounding healthy tissue. Novartis is continuing to expand its radioligand therapy pipeline, with ongoing clinical studies evaluating applications in multiple tumor types, including prostate, breast, colon, lung, brain, and pancreatic cancers.

Novartis has developed specialized manufacturing and logistics capabilities to support the production and distribution of radioligand therapies globally. The expansion of the U.S. manufacturing network is intended to support future growth as these therapies are introduced for earlier stages of treatment and for additional cancer indications.

About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.